Biotech Co.* (Country; Symbol) |
Pharma Co. (Country) |
Product | Terms/Details (Date) |
Clinical Data Inc. (CLDA) |
Merck KGaA (Germany) | Clinical Data exercised its right to manufacture vilazodone | The original deal with Clinical Data subsidiary Genaissance Pharmaceuticals Inc. was signed in 2004; Merck gets about $1.6M in Clinical Data stock (8/17) |
Giaconda Ltd. (Australia; ASX:GIA) |
Orphan Australia Pty. Ltd. (Australia) | Orphan intends to license Giaconda's Crohn's disease product Myoconda | The deal would give Orphan exclusive rights in Australia, South Africa, Namibia and Asia; terms would be worked out later (8/1) |
Calando Pharmaceuticals Inc. (majority owned by Arrowhead Research Corp.) |
Agilent Technologies Inc. | Agilent will manufacture the active siRNA component in Calando's RNAi product CALAA01 | The siRNA anticancer agent is in preclinical development; terms of the deal were not disclosed (7/26) |
Lipoxen plc (UK: AIM:LPX) |
Serum Institute of India Ltd. (India) | SIIL will develop technology for the manufacture of polysialic acid and its derivatives for Lipoxen | The technology will be used in the development of PolyXen, a natural biopolymer for pegylation of protein drugs (8/3) |
Lpath Inc. (OTC BB:LPTN) |
Laureate Pharma Inc. | Laureate will provide manufacturing and related services for Lpath's Sphingomab | The preclinical candidate is a humanized monoclonal antibody specific for sphingo- sine-1-phosphate; terms of the deal were not disclosed (8/22) |
Valera Pharmaceuticals Inc.* |
Spepharm Holding BV (the Netherlands) | Spepharm got exclusive rights to market Vantas and Supprelin-LA in the European Union, Switzerland and Norway | Valera will own 19.9% of Spepharm, and will get royalties of 40% on sales of the implant products, for treating prostate cancer and central precocious puberty, respectively (7/20) |
Notes: | |||
# The information in the chart does not cover agricultural agreements or those between biotech companies. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
AIM = Alternative Investment Market; ASX = Australian Stock Exchange; OTC BB = Over-the-Counter Bulletin Board. |